FRCP Rule 34
Unless otherwise stipulated or ordered by the court, these procedures apply to producing documents or electronically stored information:
- A party must produce documents as they are kept in the usual course of business or must organize and label them to correspond to the categories in the request;
- If a request does not specify a form for producing electronically stored information, a party must produce it in a form or forms in which it is ordinarily maintained or in a reasonably usable form or forms; and
- A party need not produce the same electronically stored information in more than one form.
US states have statutes that can be used to authorize the court to order parties in possession or control of documents to permit other parties to inspect and copy them before trial.
-
SEC hints long-awaited e-delivery rule could be imminent
House lawmakers are also moving to allow electronic investor disclosures and communications, but the SEC may act first.
Alexander Barzacanos1 min read
-
SEC’s Atkins praises Texas corporate law, promises to scale back disclosure rules
Could Texas’s recently enacted law SB 29 shape the contours of corporate law?
Alexander Barzacanos2 min read
-
Atkins glosses SEC agenda in House speech
The SEC chief touched on his plans to “Make IPOs great again,” review the costs of the Consolidated Audit Trail and PCAOB, and support crypto clarity.
Alexander Barzacanos2 min read
-
SEC’s Daly mulls strategy for e-delivery, recordkeeping clarity, and AI as firms automate
“What if we reimagined disclosure using large language models?”
Alexander Barzacanos1 min read
-
FCA consults on admissions and disclosures for cryptoassets
The A&D regime will apply to the admission to trading of qualifying cryptoassets on cryptoasset trading platforms that allow retail participation.
Sam Robinson | CMS, Yasmin Johal | CMS7 min read
-
Third‑party disclosure: a practical guide for pharmaceutical compliance and risk teams
Principal third-party disclosure mechanisms and the common pitfalls for pharmaceutical compliance and risk teams.
-
SEC brings action against biotech firm for false and misleading statements
The SEC found fault with the firm for how it reported cardiovascular safety results to investors regarding its drug, Roxadustat.
Julie DiMauro3 min read
-
Summer of CSRD Redux: Changes to European Sustainability Reporting Standards
An in-depth look at EFRAG’s proposed changes to the ESRS 1 General Requirements Standard.
